Aligos Therapeutics Stock Forward View - Simple Moving Average
| ALGS Stock | USD 7.63 0.22 2.97% |
Momentum
Impartial
Oversold | Overbought |
EPS Estimate Next Quarter -2.42 | EPS Estimate Current Year -6.53 | EPS Estimate Next Year -5.02 | Wall Street Target Price 80.25 | EPS Estimate Current Quarter -2.49 |
Hype-based context for Aligos Therapeutics connects recent headlines with price response and peer activity.
The Simple Moving Average forecasted value of Aligos Therapeutics on the next trading day is expected to be 7.52 with a mean absolute deviation of 0.36 and the sum of the absolute errors of 21.41.Aligos Therapeutics after-hype prediction price | $ 7.34 |
This sentiment layer is designed to be read with forecasting, technical, analyst, earnings, and momentum context.
Use Historical Fundamental Analysis of Aligos Therapeutics to cross-verify projections for Aligos Therapeutics. The historical series provides projection context.Aligos Therapeutics Additional Predictive Modules
Most predictive techniques to examine Aligos price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Aligos using various technical indicators. When you analyze Aligos charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Simple Moving Average Price Forecast For the 14th of March 2026
Given 90 days horizon, the Simple Moving Average forecasted value of Aligos Therapeutics on the next trading day is expected to be 7.52 with a mean absolute deviation of 0.36 , mean absolute percentage error of 0.23 , and the sum of the absolute errors of 21.41 .Please note that although there have been many attempts to predict Aligos Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Aligos Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Aligos Therapeutics | Aligos Therapeutics Price Prediction | Research Analysis |
Forecasted Value
This next-day forecast for Aligos Therapeutics uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Moving Average forecasting method's relative quality and the estimations of the prediction error of Aligos Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Aligos Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 112.9691 |
| Bias | Arithmetic mean of the errors | 0.104 |
| MAD | Mean absolute deviation | 0.3628 |
| MAPE | Mean absolute percentage error | 0.0436 |
| SAE | Sum of the absolute errors | 21.405 |
Mean reversion in Aligos Therapeutics' price occurs when temporary dislocations - caused by sentiment extremes, news events, or liquidity shocks - correct back toward the stock's historical fair value.
After-Hype Price Density Analysis
Understanding Aligos Therapeutics' probability distribution helps investors calibrate position size to their risk tolerance. The tails of the Aligos Therapeutics distribution capture low-probability but high-impact outcomes that naive point estimates ignore.
Next price density |
| Expected price to next headline |
Estimiated After-Hype Price Volatility
Using Aligos Therapeutics' historical news impact data, we estimate the likely price corridor for the next trading session after a significant headline. Aligos Therapeutics' after-hype downside and upside margins for the prediction period are 2.29 and 12.39, respectively. Note that past news reactions for Aligos Therapeutics are not guaranteed to repeat, particularly in novel market environments.
Current Value
The after-hype framework applied to Aligos Therapeutics assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Aligos Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aligos Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Aligos Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.67 | 5.05 | 0.29 | 0.03 | 8 Events | 7 Events | In 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
7.63 | 7.34 | 3.80 |
|
Hype Timeline
Aligos Therapeutics is presently traded for 7.63. The company has historical hype elasticity of -0.29, and average elasticity to hype of competition of 0.03. Aligos is forecasted to decline in value after the next headline, with the price expected to drop to 7.34. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -3.8%, whereas the daily expected return is presently at -0.67%. The volatility of related hype on Aligos Therapeutics is about 12948.72%, with the expected price after the next announcement by competition of 7.66. About 56.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.62. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aligos Therapeutics recorded a loss per share of 13.54. The company had not issued any dividends in recent years. The firm completed a 1:25 stock split on 19th of August 2024. Given the investment horizon of 90 days the next forecasted press release will be in 8 days. Use Historical Fundamental Analysis of Aligos Therapeutics to cross-verify projections for Aligos Therapeutics. The historical series provides projection context.Related Hype Analysis
Understanding how Aligos Therapeutics' direct competitors react to news events helps investors anticipate contagion effects and sector-wide sentiment shifts that may affect Aligos Therapeutics's performance.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| MRSN | Mersana Therapeutics | 0.20 | 5 per month | 2.27 | 0.14 | 7.25 | -6.26 | 210.61 | |
| KZR | Kezar Life Sciences | 0.03 | 9 per month | 1.51 | 0.16 | 2.96 | -1.54 | 12.09 | |
| FGEN | FibroGen | -0.96 | 7 per month | 0.00 | -0.04 | 4.33 | -5.28 | 28.75 | |
| XFOR | X4 Pharmaceuticals | 0.32 | 9 per month | 4.06 | 0.02 | 7.57 | -7.08 | 22.98 | |
| TPST | Tempest Therapeutics | -0.09 | 5 per month | 0.00 | -0.09 | 4.70 | -6.30 | 26.82 | |
| BRNS | Barinthus Biotherapeutics plc | -0.02 | 5 per month | 0.00 | -0.04 | 5.71 | -6.67 | 20.94 | |
| OKUR | OnKure Therapeutics | 0.10 | 6 per month | 3.53 | 0.08 | 7.76 | -5.77 | 20.86 | |
| CVM | CEL SCI Corp | 0.82 | 4 per month | 0.00 | -0.12 | 8.37 | -9.05 | 31.96 | |
| INMB | INmune Bio | -0.04 | 7 per month | 0.00 | -0.09 | 6.37 | -6.58 | 18.34 | |
| SKYE | Skye Bioscience Common | 0.03 | 12 per month | 0.00 | -0.10 | 10.19 | -7.92 | 25.49 |
Other Forecasting Options for Aligos Therapeutics
The price movement of Aligos is a central concern for all potential investors, regardless of their level of expertise. Aligos Stock price charts can be difficult to interpret due to the noise present in the data.Aligos Therapeutics Related Equities
The following equities are related to Aligos Therapeutics within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Aligos Therapeutics against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Aligos Therapeutics Market Strength Events
Market strength indicators applied to Aligos Therapeutics stock help investors assess the relative momentum and resilience of the security in different market environments. By using these indicators, traders can make more informed decisions about when to buy or sell Aligos Therapeutics.
Aligos Therapeutics Risk Indicators
Risk indicator analysis for Aligos Therapeutics is essential for accurately projecting its future price trajectory. By identifying the level of risk embedded in Aligos Therapeutics' investment, investors can make informed decisions about position sizing and risk mitigation.
| Mean Deviation | 4.29 | |||
| Standard Deviation | 5.47 | |||
| Variance | 29.91 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Aligos Therapeutics
Coverage intensity for Aligos Therapeutics matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Aligos Therapeutics Short Properties
Short sentiment tied to Aligos Therapeutics matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 9.9 M | |
| Cash And Short Term Investments | 77.8 M |
Additional Tools for Aligos Stock Analysis
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Holdings Check your current holdings and cash position to determine if your portfolio needs rebalancing | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |